Buscar
Mostrando ítems 1-10 de 119
Stem cell-like Subtypes in Triple-Negative Breast Cancer.
(Academia Nacional de Medicina venezolana., 2022)
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
(Clinical Medicine Insights: OncologyPE, 2019)
Background: Triple-negative breast cancer (TNBC) is a heterogeneous disease with aggressive biology and complex tumor evolution.
Our purpose was to identify enrichment patterns of genomic alterations in metastatic ...
Ganancias y pérdidas genómicas en tumores de cáncer de mama con fenotipo triple negativo y pérdida de expresión de BRCA1
(2016)
El cáncer de mama triple negativo (TNBC) definido por la ausencia de expresión del receptor de estrógeno, del receptor de progesterona y del receptor 2 del factor de crecimiento epidermal (HER2), representa un grupo agresivo, ...
Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study
(2023)
Background Latin American (LA) studies on triple-negative breast cancer (TNBC) and their characteristics are scarce. This forces physicians to make clinical decisions based on data obtained from studies that include ...
Impacto de la mutación BCRA 1-2 en sobrevida global en pacientes con cáncer de mama triple negativo metastásico en un hospital general de Lima- Perú durante el año 2021-2022
(Universidad Peruana Cayetano HerediaPE, 2023)
Introducción: El cáncer de mama es una de las neoplasias más frecuentemente diagnosticada dentro de los subtipos el más agresivo es el triple negativo (TNBC),se desarrolla en un 15 – 25 % de las mujeres con cáncer de mama, ...
Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth
(Nature Publishing Group, 2020-04)
Triple negative breast cancer (TNBC) refers to tumors that do not express clinically significant levels of estrogen and progesterone receptors, and lack membrane overexpression or gene amplification of ErbB-2/HER2, a ...
Cetuximab and IL-15 Promote NK and Dendritic Cell Activation In Vitro in Triple Negative Breast Cancer
(MDPI AG, 2020-06)
Triple Negative Breast Cancer (TNBC) treatment is still challenging, and immunotherapy is a potential approach in this tumor subtype. Cetuximab is an IgG1 monoclonal antibody (mAb) directed against Epidermic Growth Factor ...
Estudo da infecção por Trypanosoma cruzi em células normais e tumorais de mama
(Universidade Federal de UberlândiaBrasilCiências Biológicas, 2021)
Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells
(2022)
Triple-negative breast cancer (TNBC) represents a challenge in the search for new therapeutic targets. TNBCs are aggressive and generate resistance to chemotherapy. Tumors of TNBC patients with poor prognosis present a ...